tiprankstipranks
Advertisement
Advertisement
Veracyte Oncology Portfolio Progress Supports Buy Rating and Unchanged $48 Price Target
PremiumRatingsVeracyte Oncology Portfolio Progress Supports Buy Rating and Unchanged $48 Price Target
18d ago
Veracyte’s TrueMRD Monitoring Test receives coverage from CMS
Premium
The Fly
Veracyte’s TrueMRD Monitoring Test receives coverage from CMS
1M ago
Veracyte price target raised to $42 from $40 at Canaccord
Premium
The Fly
Veracyte price target raised to $42 from $40 at Canaccord
1M ago
Veracyte announces new data at AUA 2026 on Decipher portfolio
PremiumThe FlyVeracyte announces new data at AUA 2026 on Decipher portfolio
2M ago
Veracyte price target lowered to $40 from $43 at Canaccord
Premium
The Fly
Veracyte price target lowered to $40 from $43 at Canaccord
2M ago
Veracyte initiated with a Buy at Jefferies
Premium
The Fly
Veracyte initiated with a Buy at Jefferies
2M ago
Veracyte price target lowered to $37 from $48 at Morgan Stanley
PremiumThe FlyVeracyte price target lowered to $37 from $48 at Morgan Stanley
3M ago
Veracyte Inc. Signals Durable Growth in Earnings Call
Premium
Company Announcements
Veracyte Inc. Signals Durable Growth in Earnings Call
3M ago
Veracyte: Accelerating Growth, Expanding Margins, and Pipeline-Driven Upside Support a Raised $48 Price Target
Premium
Ratings
Veracyte: Accelerating Growth, Expanding Margins, and Pipeline-Driven Upside Support a Raised $48 Price Target
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100